Solubility and Bioavailability Enhancement of a Novel Liquisolid Compact of Gliclazide

Abstract

The study investigates the use of liquisolid compacts, a revolutionary pharmaceutical formulation technique, to improve the dissolution rate of weakly water-soluble medicines, with gliclazide as a case study. Nonvolatile solvents such as polyethylene glycol (PEG) 400, tween 80, and propylene glycol were used to make liquidsolid tablets, together with carrier ingredients such as Avicel PH102, starch, or HPMC, and Aerosil 200 as a coating material. The drug-excipient interaction was studied utilizing techniques such as differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FTIR). The produced tablets were tested for appearance, weight fluctuation, hardness, friability, drug content, and in-vitro drug release before being compared to traditional tablets (control) to determine the improvement in dissolution rate. The optimum formulation was subjected to stability tests. FTIR and DSC investigations revealed no significant drug-excipient interactions. All pill formulations met the requirements. Liquisolid tablets significantly increased gliclazide dissolving when compared to conventional tablets, which was ascribed to improved wetting qualities and particle effective surface area. According to the study, the liquisolid technique is a potential approach for increasing the dissolving rate of poorly soluble pharmaceuticals. The tablets remained stable at accelerated settings for three months, demonstrating the efficacy and feasibility of the liquisolid approach in increasing gliclazide dissolving rates.